Says respond else face action Annoyed by the non-submission of reports regarding illegal clinical trials of breast cancer drug, the National Human Rights Commission (NHRC) has issued notices to the Union health ministry and the Andhra Pradesh government. It has asked the Centre and the state government to respond within six weeks or face action. The commission had in June last year sent notices to the Union health secretary, secretary of the...

-The Times of India After being dormant for nearly a year, the H1N1 virus has made an appearance in Mumbai. A six-year-boy from Mulund tested positive for the virus that claimed several lives during and after the 2009 pandemic, and still continues to haunt neighbouring Pune. The virus had remained 'underground' for the better part of 2011, but suddenly struck Pune in March this year killing five and affecting 95 people in...

As the biotech industry takes heart from the prime minister’s remark, a fresh report shows India’s regulation and expertise on GM crops are sloppy BUOYED by the prime minister’s remark that NGOs were responsible for the moratorium on the release of GM or Bt brinjal, the biotech industry is stepping up its campaign to get it lifted along with “all constraints in the research and development work of biotech crops”. It...

Token relief to individual taxpayers will cost the exchequer Rs. 4,500 crore In a “pragmatic and domestic growth-oriented” budgetary exercise aimed at shoring up investor confidence and investment, Union Finance Minister Pranab Mukherjee on Friday sought to tap indirect taxes, especially service tax, to rake in an additional Rs. 45,940 crore into his kitty. Presenting the budget for 2012-13 in Parliament, Mr. Mukherjee provided a token relief to individual taxpayers that will cost...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...